Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
Profitability ratio essays
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Introduction Ajax electronics ' problem is that they have too much accounts receivable, inventory and liabilities, and I recommend them to stop selling defibrillators and focus on industrial sensors, which they will have lower competition and a gross margin up to 40%, and get some with financial and administrative skills on the board or as an manager. Analysis Ajax electronics got into the defibrillator business because Mr.Robert thought he could achieve a gross margin over than 40%, but the numbers show that Ajax electronics is struggling and always seemed lack of cash. Sales growth after 2000 were only 9%, which the average annual sale growth rates range from 10% to 30% in their industry. The lack of cash is explained by the current liquidity ratio …show more content…
When we take a close look at the accounts receivable on Ajax 's books, we will find that if we rule out the $6,000 from General Service Administration, over 80% of the accounts receivable over 30 days are from hospitals or medical product distributors, which are all defibrillator clients. On the other hand, only three clients that buy sensors turn in their money in more than 30 days. The industry average has a low of 40 days to a high of 80 days, showing that the sensors market has a great advantage on accounts receivable, and focusing on sensor clients and getting rid of defibrillator clients will be the best way to tune down accounts receivable for $75,000 as suggested. Also, while the sensors have little competition and has proven to achieve gross margins of 40%, the low-end defibrillator market is full of competitors and has a limit of 25%. Even though switching to manufacturing high-end defibrillators could bring a gross margins of 40%, the market is limited by saturation and it will be too late to switch from low-end to high-end right
Medtronic (Minneapolis) and Edwards Lifesciences (Irvine, California) were not strangers in patent lawsuits. Edwards is specializing in the production of artificial heart valves and new hemodynamic monitoring technology, whereas Medtronic is specializing in the production of medical devices. In the past, the two companies have problems in patent infringement lawsuits over annuloplasty procedures and endovascular graft (1,2). However, currently another latest patent infringement lawsuit has been occurred and reported between Medtronic and Edwards Lifesciences. Edwards claimed that it has prior intellectual property rights on the new transcatheter aortic valve technology.
The CNS Company is already a successful company due to the achievements of its breathing right strips. In my analysis we learned that they already do a lot of things right. What they need to be aware of is the different economical situations in the global marketplace, there are different ways that the product is approved abroad, and there is competition lurking. CNS needs to continue to leverage their strengths, but capitalize on their opportunities and benchmark the competition.
The 3 percent decline in sales causing a 21 percent decline in profits can be attributed to the identification of the accounting concept of operating leverage. Operating leverage is what business managers apply to boost small changes in revenue into sizable changes in profitability. Fixed cost is the force managers use to attain disproportionate changes between revenue and profitability. Therefore, when all costs are fixed every sales dollar contributes one dollar toward the potential profitability of a project. Once sales dollars cover fixed costs, each additional sales dollar represents pure profit. A small change in sales volume can significantly affect profitability (Edmonds, Tsay, & Olds, 2011). So, therefore, if sales volume increases,
Sales growing at a faster rate than cost of goods sold. Projected FY4 and FY5 also had projected sales growing faster than cost of goods sold. See graph for details (Derived from Exhibit 1).
These programmers communicate with the pacemaker via wireless radio frequency as well as telemetry to make device adjustments and monitor device functions. Physician programmers require no authentication to program pacemaker devices [15]. This is true for all pacemakers. The lack of required authentication is a point of concern because of the potential for risk. As was mentioned, pacemaker manufacturers warn of prolonged exposure to cellphones, metal detection systems, and other electrical devices for risk of misinterpretation by the pacemaker. The electrical impulses these devices emit could be read by the pacemaker as a heartbeat which could cause the device to malfunction or fail [17]. Deliberate attacks on pacemakers have been tested and provide troubling results. Within a 50-foot proximity, an attacker can deliver a lethal 830v jolt to a user’s heart from a laptop [13]. On the hard drives of two pacemaker devices both encrypted and unencrypted data was found by researchers for the technology research company WhiteScope. The researchers found that one unnamed pacemaker device stores unencrypted PHI such as patient and physician names, treatment data, and, most concerning, patient social security number [15]. This information can be collected and sold through black market
If Lars decides to invest around $6 million more in research and development, it is highly risky as the company’s survival depends largely on the success of the launch of Ray’s new product into the market.
Analyzing Wal-Mart's annual report provides a positive outlook on Wal-Mart's financial health. Given the specific ratios and its comparison to other companies in the same industry, Wal-Mart is leading and more than likely continue its dominance. Though Wal-Mart did not lead in all numbers, its leadership and strong presence of the market cements the ongoing success. The review of the current ratio, quick ratio, inventory turnover ratio, debt ratio, net profit margin ratio, ROI, ROE, and P/E ratio all indicate an upbeat future for the company. The current ratio, which is defined as current assets divided by current liabilities, is a measure of how much liabilities a company has compared to its assets. Wal-Mart in the year of 2007 had a current ratio of .90, and as of January 2008 it had a current ratio of .81. The quick ratio, which is defined as current assets minus inventory divided by current liabilities, is a measure of a company's ability pay short term obligations. Wal-Mart in the year of 2007 had a quick ratio of .25, and as of January 2008 it had a ratio of .21. Both the current ratio and quick ratio are a measure of liquidity. Wal-Mart is not as liquid as its competitors such as Costco or Family Dollar Stores Inc. I believe the reason why Wal-Mart is not too liquid is because they are heavily investing their profits for expansion and growth. Management claims in their financial report that holding their liquid reserves in other currencies have helped Wal-Mart hedge against inflationary pressures of the US dollar. The next ratio to look at is the inventory ratio which is defined as the cost of sales divided by average inventory. In the year of 2007, Wal-Mart’s inventory ratio was 7.68, and as of January 2008 it was 7.96. Wal-Mart has a lot of sales therefore it doesn’t have too much a problem of holding too much inventory. Its competitors have similar ratios though they don’t have as much sales as Wal-Mart. Wal-Mart’s ability to sell at lower prices for same quality, gives them the edge against its competition. As of the year 2007, Wal-Mart had a debt ratio of .58, and as of January 2008, it had a debt ratio of .59. The debt ratio is calculated by dividing the total debt by its total assets. Wal-Mart has a lot more assets than it does debt so Wal-Mart is not overleveraged.
Andrews is a sensor manufacturer in the market. While the company has been unable to develop a straightforward competitive advantage over the course of the past three years, the competitive landscape of the market has become a significant source of concern for the company’s leadership. There are other companies out there who produce better products, or are able to compete strictly based on price cuts. It came to the CEO’s attention that there is an opportunity for Andrews to shift a large portion of its production to an offshore location. This decision will not only allow Andrews to reduce its labour and material costs, but will also allow for improved distribution practices.
The Zoll LifeVest (K0606-wearable cardioverter defibrillator) for the dates of 09/02/2015, 10/02/2015, 12/02/2015, 01/02/2016-02/02/2016 was not medically necessary for the treatment of this member’s condition.
“US Markets for Heart Valves.” SAGE Sourcebook of Modern Biomedical Devices: Business Environments, 2007. 21 April 2011.
Our Company will be extremely successful due to the fact that we are concentrated on creating a product that will met our customers needs, wants, and demands. The fact that our prospective consumers do not have to continuously buy new batteries or recharge them is very appealing, not to mention that they will save tho...
First of all we need to understand the type of technology this device represents. Is this a sustaining innovation? Or is this a completely new disruptive product? After fully understanding this aspect we can make better decisions regarding the future of the firm and its product. This device offers many benefits that current products do not. As explained earlier, this device is extremely portable, offering emergency rooms the flexibility and convenience they seek to provide patients with the best treatment possible. Likewise, this product will come in at a price point much lower than current echocardiographies, further separ...
What I wanted to talk about today is this life save device called a automated external defibrillator. It has become the number one way to resuscitate a person who has had a cardiac arrest unwitnessed by emergency medical services and who is still in persistent ventricular fibrillation or ventricular tachycardia. Many people have played a big role in creating this device to become more efficient, smaller and easier to use for the general public. Here are just to name a few that played a part in the creation for this device: Claude Beck, James Rand, Paul Zoll, and Frank Pantridge. The first use of a defibrillator on a patient was in 1947 on a 14 year old boy. Claude Beck was performing a open-chest surgery when the boy went into fibrillation. Beck manually massaged his heart for 45 minutes until the arrival of the defibrillator. The defibrillator he used during surgery was made by James Rand and had silver paddles the size of large teaspoons. In 1956, Paul Zoll performed the first successful external defibrillation with a more powerful defibrillator. A major breakthrough in emergency medicine occur in 1965. At the time a majority of coronary deaths occurred outside of the hospital setting since defibrillator required a main power source and were only available in hospitals it made them pretty much useless in saving lives outside of a hospital setting. Frank Pantridge often referred to as the Father of Emergency Medicine, made the first portable defibrillator in 1965. This device was power by a car battery and weighted approximately 70 kg (155 lbs). By 1968 he was able to create a defibrillator that was safer to use and only weighted 3 kg (6-7 lbs). It was argued that their was a possibility of misuse of the device if given to a unt...
DataClear had also recorded very impressive sales growth in its first two years and, given the projections, were looking at 300 percent average revenue growth thru '02. The case analysis available shows that DataClear has a $600 million annual domestic market for its current product and $1.2 billion when you add in the global market in telecommunications and financial services. With product expansion, there was a potential annual $2.7 billion market ($1.5billion domestic/$1.26 billion abroad) to target in the telecommunications, financial services, chemical, petrochemical, and pharmaceutical industries combined.
All these improvements will boost profitability by identifying at least or more that EUR 30 mio required by U.S.A headquarters. However, we believe it is not realistic to manage all this turnaround in 1 year’s time. It might take from 2 – 3 years.